Factory 99% Sofosbuvir Powder CAS 1190307-88-0 Chemical Intermediate Sofosbuvir

• Customization: Available
• Powder: Yes
• Customized: Customized
• Model NO.: A551
• Suitable for: Elderly, Children, Adult
• State: Powder
• Purity: >99%
• Name: Sofosbuvir
• CAS: 1190307-88-0
• Appearance: White Powder
• Assay: 99%
• OEM: Available
• Sample: Available
• Suitable: Adult
• MOQ: 10g
• Function: Chemical Intermediate
• Transport Package: Foil Bag
• Specification: 99
• Trademark: /
• Origin: China
• Production Capacity: 10000 Kgs Per Month

Product Description

Product Name	Sofosbuvir
Appearance	White Powder
CAS NO.	1190307-88-0
MF	C22H29FN3O7PS
Storage	Keep in a cool, dry, dark location

 

Sofosbuvir, with the molecular formula C22H29FN3O7PS, is a direct-acting antiviral agent (DAA) primarily used in the treatment of hepatitis C. It belongs to a class of drugs known as nucleoside/nucleotide inhibitors, specifically targeting the NS5B polymerase of the hepatitis C virus (HCV).

 

1. Treatment of HCV Infection: Sofosbuvir is a cornerstone of HCV therapy, effective against multiple genotypes of the virus. It is often prescribed in combination with other DAAs to achieve sustained virologic response (SVR), which signifies the elimination of the virus from the body.

2. Pan-Genotypic Activity: One of its key advantages is its broad-spectrum activity against HCV genotypes, making it a versatile option in clinical practice where the genotype may not always be known beforehand.

3. Interferon-Free Regimens: Sofosbuvir-based regimens have significantly simplified HCV treatment protocols by allowing for interferon-free therapy, thereby reducing side effects and improving patient adherence.

1. Inhibition of NS5B Polymerase: By binding to the NS5B polymerase, sofosbuvir disrupts the viral replication process. This enzyme is crucial for the synthesis of HCV RNA, and its inhibition halts viral production.

2. High Barrier to Resistance: The molecular structure of sofosbuvir contributes to a high genetic barrier against the emergence of resistance mutations in HCV. This ensures long-term efficacy and reduces the likelihood of treatment failure.

3. Improved Patient Outcomes: By effectively suppressing HCV replication, sofosbuvir contributes to significant improvements in liver function, reduction in liver fibrosis progression, and overall patient survival rates.